Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Deferred Revenue (2016 - 2021)

Historic Current Deferred Revenue for Abeona Therapeutics (ABEO) over the last 11 years, with Q4 2021 value amounting to $296000.0.

  • Abeona Therapeutics' Current Deferred Revenue changed 0.0% to $296000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $296000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $296000.0 for FY2021, which is 0.0% changed from last year.
  • As of Q4 2021, Abeona Therapeutics' Current Deferred Revenue stood at $296000.0, which was down 0.0% from $296000.0 recorded in Q3 2021.
  • Over the past 5 years, Abeona Therapeutics' Current Deferred Revenue peaked at $2.6 million during Q4 2017, and registered a low of $296000.0 during Q4 2018.
  • In the last 5 years, Abeona Therapeutics' Current Deferred Revenue had a median value of $296000.0 in 2018 and averaged $500117.6.
  • Per our database at Business Quant, Abeona Therapeutics' Current Deferred Revenue surged by 33189.37% in 2017 and then plummeted by 8861.54% in 2018.
  • Over the past 5 years, Abeona Therapeutics' Current Deferred Revenue (Quarter) stood at $2.6 million in 2017, then tumbled by 88.62% to $296000.0 in 2018, then changed by 0.0% to $296000.0 in 2019, then changed by 0.0% to $296000.0 in 2020, then changed by 0.0% to $296000.0 in 2021.
  • Its Current Deferred Revenue was $296000.0 in Q4 2021, compared to $296000.0 in Q3 2021 and $296000.0 in Q2 2021.